000127048 001__ 127048
000127048 005__ 20240228140903.0
000127048 0247_ $$2doi$$a10.1038/leu.2015.80
000127048 0247_ $$2pmid$$apmid:25787915
000127048 0247_ $$2ISSN$$a0887-6924
000127048 0247_ $$2ISSN$$a1476-5551
000127048 0247_ $$2altmetric$$aaltmetric:3813850
000127048 037__ $$aDKFZ-2017-03074
000127048 041__ $$aeng
000127048 082__ $$a610
000127048 1001_ $$aMai, E. K.$$b0
000127048 245__ $$aPhase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
000127048 260__ $$aBasingstoke$$bNature Publ. Group$$c2015
000127048 3367_ $$2DRIVER$$aarticle
000127048 3367_ $$2DataCite$$aOutput Types/Journal article
000127048 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521622312_920
000127048 3367_ $$2BibTeX$$aARTICLE
000127048 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127048 3367_ $$00$$2EndNote$$aJournal Article
000127048 520__ $$aWe aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response rates or better (⩾VGPR) in 504 newly diagnosed, transplant-eligible multiple myeloma patients. VCD was found to be non-inferior to PAd with respect to ⩾VGPR rates (37.0 versus 34.3%, P=0.001). The rates of progressive disease (PD) were 0.4% (VCD) versus 4.8% (PAd; P=0.003). In the PAd arm, 11 of 12 patients with PD had either renal impairment (creatinine ⩾2 mg/dl) at diagnosis or the cytogenetic abnormality gain 1q21, whereas no PD was observed in these subgroups in the VCD arm. Leukocytopenia/neutropenia (⩾3°) occurred more frequently in the VCD arm (35.2% versus 11.3%, P<0.001). Neuropathy rates (⩾2°) were higher in the PAd group (14.9 versus 8.4%, P=0.03). Serious adverse events, both overall and those related to thromboembolic events, were higher in the PAd group (32.7 versus 24.0%, P=0.04 and 2.8 versus 0.4%, P=0.04). Stem cell collection was not impeded by VCD. VCD is as effective as PAd in terms of achieving ⩾VGPR rates with fewer PD and has a favorable toxicity profile. Therefore, VCD is preferable to PAd as induction therapy.
000127048 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000127048 588__ $$aDataset connected to CrossRef, PubMed,
000127048 650_7 $$2NLM Chemicals$$aBoronic Acids
000127048 650_7 $$2NLM Chemicals$$aPyrazines
000127048 650_7 $$069G8BD63PP$$2NLM Chemicals$$aBortezomib
000127048 650_7 $$07S5I7G3JQL$$2NLM Chemicals$$aDexamethasone
000127048 650_7 $$080168379AG$$2NLM Chemicals$$aDoxorubicin
000127048 650_7 $$08N3DW7272P$$2NLM Chemicals$$aCyclophosphamide
000127048 7001_ $$aBertsch, U.$$b1
000127048 7001_ $$aDürig, J.$$b2
000127048 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, C.$$b3$$udkfz
000127048 7001_ $$aHaenel, M.$$b4
000127048 7001_ $$aBlau, I. W.$$b5
000127048 7001_ $$aMunder, M.$$b6
000127048 7001_ $$aJauch, A.$$b7
000127048 7001_ $$aSchurich, B.$$b8
000127048 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, T.$$b9$$udkfz
000127048 7001_ $$aMerz, M.$$b10
000127048 7001_ $$aHuegle-Doerr, B.$$b11
000127048 7001_ $$aSeckinger, A.$$b12
000127048 7001_ $$aHose, D.$$b13
000127048 7001_ $$aHillengass, J.$$b14
000127048 7001_ $$aRaab, M. S.$$b15
000127048 7001_ $$aNeben, K.$$b16
000127048 7001_ $$aLindemann, H-W$$b17
000127048 7001_ $$aZeis, M.$$b18
000127048 7001_ $$aGerecke, C.$$b19
000127048 7001_ $$aSchmidt-Wolf, I. G. H.$$b20
000127048 7001_ $$aWeisel, K.$$b21
000127048 7001_ $$aScheid, C.$$b22
000127048 7001_ $$aSalwender, H.$$b23
000127048 7001_ $$aGoldschmidt, H.$$b24
000127048 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/leu.2015.80$$gVol. 29, no. 8, p. 1721 - 1729$$n8$$p1721 - 1729$$tLeukemia$$v29$$x1476-5551$$y2015
000127048 909CO $$ooai:inrepo02.dkfz.de:127048$$pVDB
000127048 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000127048 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000127048 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000127048 9141_ $$y2015
000127048 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127048 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127048 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2015
000127048 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127048 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000127048 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000127048 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127048 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127048 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127048 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127048 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127048 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127048 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bLEUKEMIA : 2015
000127048 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000127048 980__ $$ajournal
000127048 980__ $$aVDB
000127048 980__ $$aI:(DE-He78)C060-20160331
000127048 980__ $$aUNRESTRICTED